Developing controlled release immune complexes to treat multiple sclerosis
开发控释免疫复合物来治疗多发性硬化症
基本信息
- 批准号:10679346
- 负责人:
- 金额:$ 7.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-05 至 2025-03-04
- 项目状态:未结题
- 来源:
- 关键词:Adaptive Immune SystemAddressAminesAntigen-Antibody ComplexAntigen-Presenting CellsAntigensAutoantigensAutoimmune DiseasesAutoimmunityBiocompatible MaterialsCellsCentral Nervous SystemCharacteristicsChargeCuesDataDendritic CellsDiseaseDisease ProgressionDrug Delivery SystemsDrug ModelingsElectrostaticsEnvironmentExhibitsFRAP1 geneGene ExpressionGoalsHigh Pressure Liquid ChromatographyImmuneImmune TargetingImmune ToleranceImmune responseImmune signalingImmune systemImmunocompromised HostImmunohistochemistryImmunologyImmunosuppressionImmunosuppressive AgentsImpairmentIn VitroInfectionInflammationInflammatoryInnate Immune SystemInsulin-Dependent Diabetes MellitusInvestigational TherapiesInvestmentsKineticsLeadLibrariesLinkLipidsLymphocyteMacrophageMeasuresModelingMolecularMorphologyMultiple SclerosisMyelinMyelin SheathNatural ImmunityNatural Killer CellsNeurologicNeuronsOligonucleotidesPathogen detectionPathway interactionsPatientsPatternPharmaceutical PreparationsPlayPolymersPredispositionPropertyQuality of lifeReactionReceptor SignalingRegulatory T-LymphocyteReporterResearchRheumatoid ArthritisRoleSeveritiesSignal PathwaySignal TransductionSirolimusStructureSurfaceT-LymphocyteTechniquesTestingTimeToll-like receptorsTrainingUnited States National Institutes of HealthWorkadaptive immunityantagonistblood-brain barrier crossingcapsulecareercareer developmentcombatcompliance behaviorcontrolled releasecrosslinkcytotoxic CD8 T cellsdensitydesigndraining lymph nodeimmune modulating agentsimmunoregulationimprovedinsightinterestmouse modelmultiple sclerosis patientmultiple sclerosis treatmentnew technologynovel therapeuticspolarized cellpost-doctoral trainingpre-clinicalreceptor functionresponsesecondary lymphoid organself assemblyskillstraffickingtreatment strategyuptake
项目摘要
In autoimmune diseases, the immune system mistakenly identifies “self”-molecules/antigens as foreign, resulting
in an orchestrated attack of the body. In multiple sclerosis (MS), the immune system attack of the protective neuronal sheath
– myelin - results in debilitating neurological impairment and poor quality of life. Current MS therapies are non-curative,
require life-long compliance, and exhibit non-specific effects that increase patient susceptibility to infection. To circumvent
MS treatment challenges, emerging therapies seek to direct myelin self-antigens (MOG) and immunomodulatory cues to
redirect the immune response. Toll-like receptors, which detect pathogen-associated patterns on antigen presenting cells
(APCs) are involved in MS. Recently, TLR9 antagonist, GpG has been shown to downregulate APC activation while
promoting TREGS. Similarly, Rapamycin (Rapa), an immunosuppressant drug has garnered interest because it inhibits major
pathways and promotes regulatory T cells (TREGS). Since coordination between the innate and adaptive immune system in
MS drives disease, the proposed study will target these pathways simultaneously to promote antigen-specific immune
tolerance in MS.
We have previously developed self-assembled carriers built entirely from immune cues – termed immune
polyelectrolyte multilayers (iPEMs) that enable combinatory delivery of multiple cues, controlled loading, and high cargo
densities. iPEMs assembled using MOG and GpG reduce TLR9 signaling while promoting TREGS but show moderate
efficacy in preclinical MS models. Since TREGS play a crucial role in moderating immune responses, the proposed work aims
to load Rapa in the core of MOG/GpG iPEMs to enable co-delivery of MOG to induce antigen-specific immune responses,
GpG to downregulate APC activity, and incorporate cross-links to control Rapa delivery to induce TREGS. In Aim 1, the
hypothesis that cross-link density in MOG/GpG (Rapa) iPEMs is correlated to release intervals will be tested. This will be
accomplished by generating a library of iPEMs from combinations of MOG, control antigen (ANT-CTRL), GpG, inactive
control ODN (ODNCTRL), as well as Rapa with distinct cross-linking conditions to control release. In Aim 2, cross-linked
iPEM release kinetics will be linked to APC activation and T cell polarization. In Aim 3, the efficacy of crosslinked iPEMs
in preclinical MS models will be assessed to test the hypothesis that dual-targeting of innate and adaptive immunity is
necessary to drive antigen-specific TREGS in MS. These studies will show that modulating both innate and adaptive immunity
is necessary to generate robust antigen-specific responses in MS and will provide insight that informs the design of new
therapies to treat MS and other autoimmune diseases. At the same time, new skills and techniques will be acquired
throughout the course of the studies to propel the goal of the trainee to lead an academic research lab focused on developing
immunomodulatory drug delivery systems after postdoctoral training.
在自身免疫性疾病中,免疫系统错误地将“自身”分子/抗原识别为外来的,从而导致免疫缺陷。
对尸体进行了精心策划的攻击在多发性硬化症(MS)中,免疫系统攻击保护性神经鞘,
- 髓磷脂-导致衰弱性神经损伤和生活质量差。目前的MS疗法是非治愈性的,
需要终生的依从性,并表现出增加患者感染易感性的非特异性作用。规避
MS治疗面临挑战,新兴疗法寻求将髓鞘自身抗原(MOG)和免疫调节因子引导至
改变免疫反应的方向Toll样受体,检测抗原呈递细胞上的病原体相关模式
最近,TLR 9拮抗剂GpG已经显示出下调APC活化,
促进TREGS。类似地,雷帕霉素(Rapa),一种免疫抑制剂药物,因为它抑制主要的
调节性T细胞(Tregs)。由于先天免疫系统和适应性免疫系统之间的协调,
MS驱动疾病,拟议的研究将同时靶向这些途径,以促进抗原特异性免疫
MS的耐受性。
我们以前已经开发出完全由免疫信号构建的自组装载体-称为免疫
可实现多个提示、受控装载和高负载的组合传送的智能多层膜(iPEM)
密度使用MOG和GpG组装的iPEM减少TLR 9信号传导,同时促进TREGS,但显示出适度的
在临床前MS模型中的疗效。由于TREGS在调节免疫反应中起着至关重要的作用,因此拟议的工作旨在
为了将Rapa装载在MOG/GpG iPEM的核心中以使得能够共同递送MOG以诱导抗原特异性免疫应答,
GpG下调APC活性,并掺入交联以控制Rapa递送以诱导TREGS。在目标1中,
将检验MOG/GpG(Rapa)iPEM中的交联密度与释放间隔相关的假设。这将是
通过从MOG、对照抗原(ANT-CTRL)、GpG、失活抗原(ANT-CTRL)和GpG的组合产生iPEM文库来完成。
对照ODN(ODNCTRL),以及具有不同交联条件的Rapa以控制释放。在目标2中,交联
iPEM释放动力学将与APC活化和T细胞极化相关。在目标3中,交联iPEM的功效
将评估临床前MS模型,以检验先天性和适应性免疫的双重靶向是
这些研究将表明,调节先天性和适应性免疫,
是在MS中产生稳健的抗原特异性应答所必需的,并将提供深入的见解,为新的免疫治疗设计提供信息。
治疗MS和其他自身免疫性疾病的疗法。与此同时,新的技能和技术将获得
在整个研究过程中,以推动受训者的目标,领导一个学术研究实验室,重点是发展
免疫调节药物输送系统后,博士后培训。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Marian Adriana Ackun-Farmmer其他文献
Marian Adriana Ackun-Farmmer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 7.18万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 7.18万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 7.18万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 7.18万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 7.18万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 7.18万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 7.18万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 7.18万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 7.18万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 7.18万 - 项目类别:
Research Grant